CardioScape is an 18-month project funded by the European Union FP7 research programme.
CardioScape aims to outline the current CVD research and innovation landscape across Europe towards establishing the extent of duplication across national research programmes and the existence of gaps that reduce opportunities for innovation
Cardiovascular diseases (CVD) – a grouping of diseases that affects the structure and/or function of the heart and blood vessels, including heart disease and stroke – is the world’s leading cause of death, claiming 17.1 million lives each year. In Europe, CVD is responsible for the death of over 4.3 million people per year in the 53 member states of the WHO European Region and more than 2 million in the EU. Recent data indicates that up to 80% of all healthcare expenditure in Europe is allocated to chronic diseases, with cardiovascular diseases alone being estimated to cost the EU economy over 192 billion euro every year.
The burden of CVD for the EU society and economy, as well as the aspirations for an Innovation Union guaranteeing improved lives and a better society for EU citizens, represents an obvious call for the discovery and deployment of innovative medical technology solutions. CVD research has also the potential of tapping into new social innovations to induce the behavioural changes which are needed to tackle the identified major societal challenge of an ageing population, both in terms of preventive measures and in providing optimal care.
CVD research is not only a crucial area in health research overall, but could become an outstanding example of research driven innovation across Europe, which, through better understanding of the causes of CVD, the development of new medicinal products and the improvement in medical technology, will boost scientific excellence and create new knowledge as drivers of future growth and prosperity.
To achieve this research potential we need to better understand the existing CVD research landscape, engage with different actors from academia and industry to shape more effective research strategies, ultimately leading to better technological, therapeutic and preventive strategies for patients and populations.
CardioScape will promote the concept of transnational collaborative projects as the cornerstone to more effective and efficient research and development strategies.
PNO UK are one of 12 partners in a unique pilot project funded through the CIP Programme of the European Commission, aimed at the development of a new approach to the delivery of public services through the use of cloud computing. The project brings together key stakeholders from across the EU including public authorities, citizens and businesses to develop a dedicated framework for cloud based public services which seeks to overcome some of the major issues that have so far prevented the full adoption of the cloud within the public sector notably in architecture, design and security.
Through the delivery of five pilots in five cities: Bremerhaven (DE), Lecce (IT), Novi Sad (RS), Santander (ES) and Stockport (UK), the project will seek to demonstrate how cloud based services can be used for the benefit of citizens and to facilitate the fictional scenario of a family moving from one member state to another and the typical complexities that such a move could entail. Taking into account administrative requirements such as registering for utilities, schooling, local taxes, social care, all through the use of use of a dedicated cloud based infrastructure, the primary goal of CLIPS is to demonstrate how the cloud can improve efficiencies and public service delivery.
At the end of the 30 month pilot project, the project will deliver a common platform with interoperable services, a transferable methodology and associated business model that will facilitate increased adoption of cloud based public services throughout the EU. It will also seek to identify and address key policy and ethical constraints that could impact the replication of the final solution. If successful, this project offers a step forward for EU cloud capabilities with significant benefits not only for public organisations at a national and regional level but also for SMEs and citizens alike.
Further details can be found at www.clips-project.eu.
CHEST is a 30 month Collaborative project co-financed with support from the European Commission through FP7. The aim of the project is simple. To provide a forum that will enable entrepreneurs and innovators from across the EU to propose new solutions that have the potential to address key societal challenges, so called ‘social innovation’. In addition to the creation of an online community platform that will facilitate the sharing and exchanging of ideas, CHEST will invest up to €2.5 Million in highly innovative ideas through the launch of two open funding rounds. Social entrepreneurs will be invited to not only propose new ideas with the potential to receive support but also evaluate and discuss the ideas of others with highest rated projects selected for funding.
- To facilitate the generation of community derived ideas that address societal challenges, supporting knowledge exchange, the development of best practice, discussion and collaborative activity.
- To invite social entrepreneurs from across Europe to submit their ideas through two open funding calls for proposals, which will then be evaluated by both the crowd community and external independent evaluators, with the highest rated proposals each receiving support for continued development and realisation.
- To transform the novel ideas selected into viable added value social initiatives.
- To communicate the results of the project across the EU and to engage with key communities, investors and incubators active with an interest in digital social innovation to ensure the sustainability of the programme with the potential to facilitate crowd funding to finance future projects and ideas
Modern use of industrial biotechnology (IB) holds the key to a bio-based economy. Deploying the full potential of biotech innovation will enable the European industry to deliver high-value products to consumers and create new commercial opportunities. New feedstock demands will lead to synergies amongst SMEs and large industrial partners. New technological developments will boost European export of technology and facilities by bringing Europe’s top sectors together: chemical industry, engineering and renewables.
However to date, major hurdles continue to hamper the full exploitation of biotechnology in Europe. These hurdles may vary from technological bottlenecks to limited availability of venture capital and fragmented policy frameworks. Funded by the European Commission, BIO-TIC was launched with the aim to establish an overview of the barriers to biotech innovation and find solutions to overcome them.
In BIO-TIC we seek to define product segments and applications that promise significant potential for Europe’s industry and society by 2030. We have now identified five major ‘bio-business cases’ which are EU-competitive and have the potential to introduce cross-cutting technology ideas. These are:
- Bioplastics PHA and PLA
- Building blocks
- CO2-based chemicals
In addition to the business cases, we are developing three in-depth ‘bio-roadmaps’. These will focus on the market potential, R&D priorities and non-technological hurdles of IB innovation. In particular, the market roadmap will provide market projections until 2030. The technology roadmap will focus on setting R&D priorities and identifying needs for pilot and demonstration of plant activities. Last but not least, the non-technological barriers roadmap will identify regulatory and non-technological hurdles that may inhibit industrial biotech innovation reaching new market opportunities. The final roadmaps will be released in July 2015.
To measure the impact of the bio-roadmaps deployment in Europe, we plan to establish a ‘bio-observatory’. This is a common regulatory framework which will describe definitions, standards, data sources and processes for systematic monitoring on the market uptake of bio-based products. Our aim is to achieve consistency in the data all along the value chain.
Find out more at: www.industrial-biotechnology.eu